RAPID ALERT

DRAP ALERT NO. Nº I/S/02-23-18

FALSIFIED AND UNREGISTERED VIAGRA 100MG TABLETS

Date: 3rd May 2023

Target Audience:

- Regulatory Field Force.
- Healthcare Professionals - Physicians, Pharmacists, and Nurses.
- General Public.

Problem Statement:

Federal Inspector of Drugs Karachi seized a sample of an unregistered product "Viagra 100mg Tablet" from the market and also sent the samples to Central Drug Laboratory, Karachi for testing/analysis. Federal Government Analyst has declared the sample as Spurious under section 3(z-b) (i) of the Drugs Act 1976.
The product detail is as under: -

Product Name	**Manufactured by (as stated on the label)**	**Remarks by Laboratory**
Viagra 100mg Tablets Batch No. **19990544AG** Mfg. Date: March 21 Exp. date: March 25	Ms. Brooklyn, Ne.	The sample is declared as a **"Spurious Drug" based on non-identification of claimed Active Ingredient.**

*** Tablet Viagra sold in the black market is not registered with DRAP, hence considered Spurious /Falsified and unregistered, and its Quality, Safety, and Efficacy are not ascertained, hence its consumption may be harmful.**

Risk Statement:

Consequences of the use of unregistered, Spurious/ Falsified Drugs include but are not limited to the followings:

- Falsified/Spurious drugs may contain toxic ingredients which are manufactured under unhygienic conditions without the proper inspection and approval of the product, which are highly injurious to human health.
- Poor-quality medicines compromise the treatment of diseases and may intensify the existing condition.

DRAP, Islamabad **92 51 9107404** **gsms@dra.gov.pk**

Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate the product. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should **immediately check** the stock, and information related to the supplier of such products should be provided to the Regulatory field force (DRAP, Provincial Health Departments and States) to ensure the removal of this product.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance at hospitals and within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this product.

Adverse reactions or quality problems experienced with the use of this product shall be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers / General public: -

Consumers should not use this product and shall contact their physician or healthcare provider if they have experienced any problem related to taking or using this drug product, and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
92 51 9107404
gsms@dra.gov.pk